TrialThe Journal of dermatology2018

Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.

Naoya Yamazaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.